Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Rips Up Competition Rulebook To Allow Collaboration On Coronavirus

Medicines For Europe Welcomes European Commission’s Temporary Framework

Executive Summary

A temporary framework has been adopted by the European Commission that will allow companies and associations to co-ordinate efforts to tackle the coronavirus pandemic without raising competition concerns. The move has been welcomed by the European off-patent industry.

You may also be interested in...



Guntern Takes Lead At Medicines For Europe

Sandoz’s Rebecca Guntern has been named as interim president of Medicines for Europe for a three-month term, after Teva’s Christoph Stoller stepped down at the end of his two-year tenure.

EU’s Health Emergency Response Plans Must Address Existing Flaws

The EU’s creation of a Health Emergency Response Authority to deal with future health threats has been welcomed by off-patent industry association Medicines for Europe. However, the organization pointed out current policy and regulatory weaknesses that must be addressed if HERA is to be successful.

Pandemic Perspectives: Cracks In Global Supply Chain Lead To Localization Trend

Weaknesses in the global pharmaceutical supply chain, exposed and exacerbated by the coronavirus pandemic, have led major markets to pursue localization policies aimed at bolstering domestic production capacity. But any significant transformation promises to take many years.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB149793

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel